3-11 Bellerose Drive
123 articles with Eagle Pharmaceuticals
FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI)
Eagle Pharmaceuticals, Inc. today announced that an additional patent has been issued related to BENDEKA® by the United States Patent and Trademark Office (USPTO).
Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Generic TREANDA entry now not expected until December 2022
Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June 2018.
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
Eagle to ship 500ml admixture product immediately
Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.
Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conferenc
Product is the generic version of Endo International plc’s original Vasostrict® formulation
The patent is directed to a technology that allows for the formulation of antibodies at high concentration.
Record 2017 revenue of $237 million
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018
A replay of the conference call will be available for one week after the call's completion by dialing 800-677-7320 (US) or 402-220-0666 (International) and entering conference call ID EGRXQ417.
The Company anticipates dosing its last subject during the first half of 2018, with study completion within twelve months, and an expected NDA filing in the fourth quarter of 2018.
Total revenue for the third quarter of 2017 grew 67% to $63.0 million compared to $37.8 million in the third quarter of 2016.
Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
Eagle submitted, and the FDA accepted for filing, its NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for PEMFEXY ready-to-dilute in December 2016.
Eagle Pharmaceuticals today announced that the Company has been issued a new patent related to its RYANODEX formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO).
Eagle Pharma Licenses Japanese Rights For Bendamustine Hydrochloride Ready-To-Dilute And Rapid Infusion Injection Products To SymBio Pharma
Eagle Pharma Announces Positive Results Of Study Conducted To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure